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MAIT cells are activated during human viral
infections
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Mucosal-associated invariant T (MAIT) cells are abundant in humans and recognize bacterial
ligands. Here, we demonstrate that MAIT cells are also activated during human viral
infections in vivo. MAIT cells activation was observed during infection with dengue virus,
hepatitis C virus and influenza virus. This activation—driving cytokine release and Granzyme
B upregulation—is TCR-independent but dependent on IL-18 in synergy with IL-12, IL-15
and/or interferon-a/b. IL-18 levels and MAIT cell activation correlate with disease severity in
acute dengue infection. Furthermore, HCV treatment with interferon-a leads to specific MAIT
cell activation in vivo in parallel with an enhanced therapeutic response. Moreover,
TCR-independent activation of MAIT cells leads to a reduction of HCV replication in vitro
mediated by IFN-g. Together these data demonstrate MAIT cells are activated following viral
infections, and suggest a potential role in both host defence and immunopathology.
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M
ucosal-associated invariant T (MAIT) cells are an
abundant and distinctive T cell subset first identified
by Porcelli et al.1 in 1993 in humans on the basis of
the invariant V-alpha chain (Va7.2-Ja33) and later described
in mice2. MAIT cells comprise B5–10% of T-cells within
the periphery and are found enriched in both the gut and in the
liver—where in humans they may represent between B12% and
50% of T-cells3–6. In both mouse and man, MAIT cells are
restricted to a bacterial riboflavin synthesis pathway-derived
ligand presented by the conserved MHC-class I like molecule
MR1 (refs 7,8). In vivo challenge models using riboflavin
synthesizing bacteria, such as Klebsiella species and
mycobacteria, have confirmed an anti-bacterial role for MAIT
cells9,10. MR1 tetramers loaded with the ligand rRL-6-CH2OH
have allowed the specific detection of human and murine
MAIT cells11.
In recent years, a number of groups have elucidated the distinct
phenotypic and functional profile of MAIT cells, characterized by
the high expression of the C-type lectin CD161 (KLRB1 or
NKR-P1A), and the capacity to secrete multiple cytokines,
including IL-17, interferon (IFN)-g and TNF-a12–16. The
distinctive phenotype of MAIT cells appears to be driven by
two key transcription factors, RORgt and PLZF3,6,13,17. RORgt
expression is linked to development of type 17 function and
expression of surface receptors such as IL23R and CCR6
(refs 5,18). This is consistent with mucosal defence and
anti-bacterial functions and also consistent with the bacterial
specificity of the receptor. PLZF is critical for development of
invariant natural killer T cell (iNKT) cells and may be responsible
for a distinct set of ‘innate’ phenotypic features, including marked
upregulation of the pro-inflammatory cytokine receptors IL-18R
and IL-12R19,20. This dual transcriptional drive suggests that
MAIT cells may possess multiple parallel functionalities or modes
of activation.
Given the specificity of the T-cell receptor (TCR), it appears
that activation of MAIT cells in vivo is driven by responsiveness
to bacteria (and some yeasts)21. However, given their ‘innate’
phenotype, broad range of effector functions, and tissue
distribution, we addressed the question of whether they may
also have evolved to respond to viral infections in vivo. If so, this
would markedly widen the role of MAIT cells in human infection.
Here, we addressed MAIT cell activation in response to a set of
major human viral pathogens both in vivo and in vitro. In vivo,
MAIT cells are activated in response to dengue virus (DENV),
hepatitis C virus (HCV) and influenza virus. In vitro, DENV,
HCV and influenza virus readily trigger MAIT cell populations in
an IL-18 dependent manner, in concert with other virally-driven
pro-inflammatory cytokines, including IFN-a/b. Activation of
MAIT cells in acute dengue correlated both with disease outcome
and with IL-18 signals. Similarly, in vivo activation of MAIT cells
during HCV therapy correlated with specific addition of IFN-a
during therapy. Taken together, these data strongly implicate a
role for MAIT cells in response to major virus infections of man
and provide a mechanism for their virus-responsive nature.
Overall, this significantly expands the pathogen response
repertoire of this abundant human T-cell subset.
Results
MAIT cell activation during acute viral infections in vivo.
Whether human MAIT cells respond during acute viral infections
remains unclear. To address this we analysed MAIT cell
activation in DENV and influenza virus infection. In this
study, MAIT cells were defined as CD161þ þVa7.2þ CD8þ
CD4CD3þ T cells. DENV infection presents with a rapid
onset of a febrile illness, which lasts around a week. After
the virus has been cleared and fever drops, patients follow two
distinct courses: an uncomplicated resolution (dengue fever; DF)
or a severe course associated with organ dysfunction and
haemorrhage (dengue haemorrhagic fever; DHF). The
determinants driving outcome are still poorly understood.
However, an aberrant immune response, around the day of
defervescence, is thought to have an important role in the
pathogenesis. We analysed MAIT cells in a longitudinal study of
peripheral blood mononuclear cells (PBMC) from a cohort
of patients with DHF or DF. Blood samples were collected at
different time points during the acute phase of infection and dates
were named in relation to the day fever subsided (day of
defervescence, day 0). Samples taken 10 or more days after the
day of defervescence (day 410) were considered convalescent.
We found a small but significant reduction in MAIT cell
frequencies between the acute phase (day 0) and the convalescent
phase (day 410) of infection (Fig. 1a,b), but no differences in
MAIT cell frequency between DHF and DF patients (Fig. 1c).
Analysis of CD38 revealed marked in vivo activation of MAIT
cells (Fig. 1d,e), which increased over the course of infection and
peaked at a critical moment for DENV infected patients—the day
of defervescence. Interestingly, patients who developed the severe
form of dengue had higher levels of MAIT cell activation as
judged by CD38 expression compared to DF patients over the
course of acute infection (Fig. 1f). MAIT cell activation resolved
to healthy control levels in the convalescent sample (Fig. 1d,e).
Granzyme B expression was also assessed due to its tight
regulation in MAIT cells, and its absence in cells from healthy
donors3,22. Furthermore, upregulation of Granzyme B is
associated with the acquisition of cytolytic function by MAIT
cells22,23. We therefore analysed Granzyme B function in acute
dengue and found this followed the same time course as that of
CD38 (Fig. 1g–i).
Given their role in mucosal defence, we next addressed the
activation of MAIT cells in response to influenza virus, a virus
with a segmented genome of negative-sense RNA. Again, patients
with acute, severe influenza virus infection had reduced MAIT
cell frequencies and an increase in Granzyme B expression on
MAIT cells (Fig. 1j–m).
Taken together, our results indicate substantial triggering of
MAIT cells in vivo during acute viral infection.
MAIT cell activation during chronic viral infection in vivo.
MAIT cells are found at high frequencies within the liver in both
healthy and diseased states3,5,13,24. Therefore, we analysed
MAIT cell activation during chronic infection with HCV, like
DENV, a member of the Flaviviridae family of positive-sense
RNA viruses. We examined MAIT cell frequency and phenotype
in the PBMC of patients with persistent and resolved HCV
infection (spontaneously or after therapy). In all HCV patients,
regardless of status, we observed a reduction in MAIT cell
frequencies compared to healthy controls (Fig. 2a). However, we
only observed upregulation of Granzyme B in patients with
prolonged HCV infection (including those who had subsequently
responded to antiviral therapy; Fig. 2b,c), and not in those
patients with prior short-lived viremia at a distant time-point
associated with acute resolving infection (thus, more akin to
convalescent DENV infection). Our results indicate substantial
activation of MAIT cells in vivo both during acute and chronic
viral infections.
Viral MAIT cell activation in vitro. Having observed MAIT cell
activation in vivo during acute and chronic viral infections,
we next established in vitro models for viral infections using
PBMCs or human CD8þ T cells, co-incubated with infected or
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virus-treated dendritic cells (DCs) or macrophages as antigen
presenting cells (APC).
MAIT cells were readily and specifically activated in response
to DENV-treated APCs (multiplicity of infection (MOI)¼ 1), as
indicated by production of IFN-g and Granzyme B (Fig. 3a,b),
as well as, expression of CD38, with minimal production of
TNF-a (Supplementary Fig. 1a–c). Activation was dependent on
the presence of APCs as DENV alone did not activate MAIT cells
(data not shown).
We next examined activation of MAIT cells in vitro in response
to influenza virus. APCs incubated with influenza virus
(MOI¼ 1) promoted strong MAIT cell activation, inducing
upregulation of CD69 and IFN-g (with minimal TNF-a
secretion), in a dose-dependent manner (Fig. 3c,d). Also,
Granzyme B expression was induced (Fig. 3e). This activation
was not restricted to laboratory-adapted influenza virus strains,
but also was seen in response to recently-circulating strains of
influenza A and B (Fig. 3f). Interestingly, MAIT cell activation
was also readily induced using PBMCs instead of purified APCs
(Supplementary Fig. 1d). Moreover, influenza virus exposure of
purified monocyte, macrophage and DC populations all led to
MAIT cell activation (Supplementary Fig. 1e).
Finally, we tested the impact of HCV on MAIT cells in vitro.
MAIT cells expressed IFN-g and Granzyme B (Fig. 3g,h), as well
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Figure 1 | MAIT cell activation during acute viral infections in vivo. PBMC’s from healthy controls (HC, n¼ 5–10), patients suffering from severe dengue
(DHF, n¼ 2–10), dengue (DF, n¼4–10) or acute, hospitalized patients infected with influenza A virus (n¼ 7–9) were analysed by flow cytometry by
gating on live CD3þCD8þCD161þ þVa7.2þ (MAIT) cells. (a,d,g) Representative flow cytometry plots. (b,e,h) Comparison between acute (day 0)
and convalescent phase (day410) of infection. (c,f,i) Comparison between DHF and DF patients. (j–m) Acute, hospitalized patients infected with influenza
virus. (b,c,j,k) MAITcell frequency as a proportion of the CD8þ Tcell population. (e,f) Percentage of CD38 expression by MAITcells. (h,i,l,m) Percentage
of Granzyme B expression by MAIT cells. Statistical significance was determined with a Wilcoxon matched-paired test (b,e,h) or Mann–Whitney test
(j,k). Bars represent means±s.e.m. ns40.05, *P 0.05, **Pr0.01, ***Pr0.001, ****Pr0.0001. conv, convalescent; Gr B, Granzyme B; HC, healthy control;
ICU, intensive care unit.
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as CD69 in response APC’s treated with HCV (MOI¼ 1), in a
dose-dependent and specific manner (Supplementary Fig. 1f–i).
Taken together, we demonstrate that MAIT cells are activated
in vitro in response to DENV, influenza virus and HCV-exposed
APCs.
Viral MAIT cell activation is dependent on cytokines. Next, we
investigated the mechanisms of MAIT cells activation in response
to viruses. The ligand presented by MR1 is derived from the
riboflavin synthesis pathway, which is not found in host cells or
viruses7. Consistent with this, using the models described above, we
confirmed by antibody blocking of MR1 that MAIT cell activation
was TCR-independent for all the viruses tested (Fig. 4a–c).
As activation was TCR-independent, we explored triggering of
MAIT cells by cytokines. Previously, we have shown that TLR8 is
capable of inducing IFN-g expression in MAIT cells via IL-12 and
IL-18 (ref. 24). In addition, IL-15 can specifically activate distinct
functions of MAIT cells in synergy with IL-12 and/or IL-18, in a
dose-dependent manner (Supplementary Figs 2 and 3)25.
We extended this finding by exploring responses to a range of
TLR ligands in PBMCs and found endosomal TLR3 was also a
potent activator (Supplementary Fig. 4). As with TLR8, TLR3
induced MAIT cell activation via IL-18 and IL-12 and not
MR112,13. TLR sensing by APC’s can occur in the absence of viral
replication26,27. To assess the requirement of viral replication for
MAIT cell activation, we used ultraviolet-irradiation of the
viruses, which prevents transcription or replication. Ultraviolet-
irradiated DENV was no longer able to activate MAIT cells
(Supplementary Fig. 5a). In contrast, ultraviolet-irradiated HCV
and influenza virus were still able to activate MAIT cells, although
less efficiently compared to untreated virus (Supplementary
Fig. 5b,c). Accordingly, DENV productively infects APCs,
whereas productive influenza virus and HCV infection is
limited in both primary and stem cell-derived human APCs
(Supplementary Fig. 5d–f)28–30. Furthermore, the level of DENV
infection correlated with MAIT cell IFN-g expression
(Supplementary Fig. 5e).
We next assessed blockade of IL-12, IL-18 and IL-15 in the
in vitro virus models. Figure 4d reveals that IL-12 and IL-18 had
the most significant impact on DENV-dependent MAIT cell
activation using DC’s, with anti-IL-18 blockade alone leading to
complete suppression of IFN-g expression. IL-18 was the most
abundant cytokine induced in DC’s in response to DENV (Fig. 4e).
Anti-IL-18 also inhibited activation of MAIT cells induced by
influenza virus, a result observed using purified APCs (Fig. 4f) or
PBMC’s (Supplementary Fig. 6a). Blockade of IL-12 and IL-15
alone or in combination had a limited impact in influenza
virus-induced MAIT cell activation using macrophages (Fig. 4f).
Accordingly, IL-18, but not IL-12 or IL-15 was secreted by
macrophages after incubation with influenza virus (Fig. 4g).
Similar to DENV and influenza virus, IL-18 had a dominant
role in HCV-induced MAIT cell activation (Fig. 4h). Addition of
further blockade with anti-IL-15 was required to achieve maximal
suppression. We assessed expression of IL-12, IL-15 and IL-18 on
macrophages after incubation with HCV (Fig. 4i). No IL-15
protein was detected, yet IL-15R (responsible for IL-15 trans-
presentation31) was upregulated by macrophages in response to
HCV, as measured by quantitative PCR (Supplementary Fig. 6b).
Overall, these experiments indicate a mechanism by which
viruses can activate MAIT cells, dependent on viral sensing
and cytokines, with a key role for IL-18, and independent of MR1
and TCR.
Virally-triggered IL-18 correlates with MAIT cell activation.
Having identified IL-18 as an important cytokine for viral MAIT
cell activation in vitro, we further explored its relevance in vivo. In
DENV infection, IL-18 levels in plasma were markedly increased
during the acute phase compared to the convalescent phase of
infection and healthy controls (Fig. 5a). In addition, patients
suffering from the severe form of dengue (DHF) had significantly
higher levels of IL-18 over the course of acute infection compared
to patient with DF (Fig. 5b). Interestingly, expression of the IL-18
receptor (IL-18R) on MAIT cells was upregulated during the acute
phase of infection and resolved to healthy control levels in the
convalescent samples (Fig. 5c). As observed for IL-18, patients with
DHF revealed higher expression of IL-18R on MAIT cells
compared to patient with DF (Fig. 5d,e). Thus, levels of IL-18 in
plasma and expression of IL-18R on MAIT cells in vivo are
upregulated during the acute phase of infection, especially in those
patients suffering from DHF. These findings show an association
with increased activation of MAIT cells and disease severity in
dengue patients (Figs 1f and 5f). These results are not restricted to
DENV infection since IL-18 protein (Fig. 5g) and mRNA (Fig. 5h)
were found readily in liver tissues from patients with HCV
infection.
Overall, these data indicate that IL-18 is not only a dominant
factor during in vitro viral MAIT cell activation, but also has an
important role in vivo.
MAIT cells respond to type I IFNs in vitro and in vivo. Type I
IFNs are also important cytokines known for their strong
antiviral activity. Previous reports have determined a crucial role
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Figure 2 | MAIT cell activation during chronic viral infection in vivo. PBMC’s from healthy controls (n¼ 20–23) or patients (n¼ 12–25) with persistent
(treatment naive, REL, NR) and resolved HCV infection (SVR, SC) were analysed by flow cytometry by gating on live CD3þCD8þCD161þ þVa7.2þ
(MAIT) cells. (a) MAITcell frequency as a proportion of the CD8þ Tcells. (b,c) Granzyme B expression by MAITcells. (b) Representative flow cytometry
plots. Bars represent means±s.e.m. Statistical significance was determined with the Kruskal–Wallis test followed by the Dunns’ test. ns40.05,
*P 0.05, **Pr0.01, ***Pr0.001, ****Pr0.0001. HC, healthy control; Gr B, Granzyme B; REL/NR, relapse/non-response; SC, spontaneous clearance;
SVR, sustained virological response; tr., treatment.
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of IFN-a/b during DENV32, influenza33 and HCV34 infections in
limiting viral replication and disease severity. We therefore
addressed whether IFN-a/b can also influence MAIT cell
activation in vitro and in vivo.
First, we tested whether IFN-a/b could trigger MAIT cells
alone or in combination. We found IFN-g secretion by MAIT
cells in response to IFN-a/b in combination with IL-12 and
IL-18, but not IL-15 (Fig. 6a), in a dose-dependent manner
(Supplementary Fig. 7). Next, we confirmed that these
TCR-independent responses to cytokines are shared with other
CD161þþ T-cell subsets, but not CD161 T-cell populations.
CD161þþCD8þ T cells that lack expression of the Va7.2Ja33
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TCR (Supplementary Fig. 8a), CD161þþ Va7.2Ja33þ CD4 T
cells (Supplementary Fig. 8b) and CD4CD8 T cells
(Supplementary Fig. 8c) could all be triggered in response to
cytokines, unlike CD161 T-cell populations (Supplementary
Fig. 8d). This is in agreement with our previous findings which
suggest that CD161-expressing lymphocytes display a shared
innate response to cytokines16.
To further explore the role of type I IFNs during viral MAIT
cell triggering, we used a vaccinia virus-encoded, soluble type I
IFN receptor (B18R)35. Macrophages treated with HCV in vitro
were incubated in the presence of B18R and T cells overnight.
Blockade of type I IFNs by B18R inhibited MAIT cell IFN-g
secretion (Fig. 6b), CD69 expression (Fig. 6c) and Granzyme B
upregulation (Fig. 6d).
IFN-a has been an important component of HCV treatment.
This gave us an opportunity to explore whether type I IFNs could
contribute to MAIT cell activation in vivo. We measured the
activation marker CD69 on MAIT cells from HCV patients
taking part in a clinical trial in which they were treated with
either sofosbuvir (SOF)þ ribavirin (RBV)þ pegylated IFN
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Figure 4 | Viral MAIT cell activation is dependent on cytokines. (a–d,f,h)
Isotype control, anti-MR1, anti-IL-12, anti-IL-15 and/or anti-IL-18 antibodies
were added to a co-culture exposed to DENV (a,d, n¼ 3–6), IAV (b,f, n¼ 5–
29) or HCV (c,h, n¼ 7–16). IFN-g expression by MAIT cells (gated on live
CD3þCD8þCD161þ þVa7.2þ cells) was analysed by flow cytometry and
is shown relative to the isotype control. (e,g,i) IL-12p70, IL-15 and IL-18
levels secreted by virus-exposed APC’s. (e) DENV-exposed DC’s (n¼4) at
42 h. (g) IAV-exposed macrophages (n¼ 7) at 48 h. (i) HCV-exposed
macrophages (n¼ 7) at 48 h. Data are representative from at least two
independent experiments. Bars represent means±s.e.m. Statistical
significance was determined with the Mann–Whitney test (a–c,e,g,i) or the
Kruskal–Wallis test followed by the Dunns’ test or the Mann–Whitney test
(d,f,h). ns40.05, *P 0.05, ***Pr0.001, ****Pr0.0001. ND, not detected.
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Figure 5 | Virally triggered IL-18 correlates with MAIT cell activation.
(a–d) PBMC’s from healthy controls (n¼ 10) or patients suffering from
severe dengue (DHF, n¼ 2–12) or dengue (DF, n¼4–12) were analysed.
(a,b) Plasma levels of IL-18. (c,d) IL-18Ra expression on MAIT cells.
(a,c) Comparison between acute (day 0) and convalescent (conv) phase
(day 410) of infection. (b,d) Comparison between DHF and DF patients.
Correlation of plasma levels of IL-18 (e) or MAIT cell CD38 expression
(f) against MAIT cell IL-18Ra expression by the Spearman-rank correlation
test. (g) Paraffin-embedded human liver tissues sections from HCV or
control patients were stained for IL-18 (brown-coloured). Scale bar, 10mm.
(h) IL-18 mRNA expression in liver biopsies from HCV patients (n¼ 55)
relative to uninfected control liver samples is shown (n¼6). Bars
represent means±s.e.m. Statistical significance was determined with the
Mann–Whitney test (b,d,h) or the Wilcoxon matched-paired test
(a,c). ns40.05, *P 0.05, ***Pr0.001, ****Pr0.0001. conv, convalescent;
HC, healthy control.
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(PEG-IFN), or only SOFþRBV, without PEG-IFN. Interestingly,
CD69 expression on MAIT cells was upregulated only in
the treatment group receiving PEG-IFN (Fig. 6e), which
corresponded with a significantly higher sustained virologic
response rate36. High CD69 upregulation was specific to
CD161þþMAIT cells and not observed on CD161CD8þ or
CD4þ T cells (Supplementary Fig. 9). These data demonstrate
that type I IFNs can contribute to MAIT cell activation in vitro
and in vivo.
Activated MAIT cells can limit HCV replication. Finally, we
explored whether viral MAIT cell activation can have a functional
impact on virus replication. We stimulated sorted MAIT cells in a
TCR-independent manner (IL-12 and IL-18) and confirmed
activation by measurement of IFN-g secretion (Fig. 7a). The cell
supernatants of unstimulated and stimulated MAIT cells were
transferred to a hepatocyte line infected with HCV expressing
luciferase, allowing measurement of HCV replication. The
activated MAIT cell supernatants were able to potently suppress
HCV replication, while no activity from control supernatants
(Fig. 7b) or from IL-12 and IL-18 (data not shown) addition to
hepatocytes was seen. Diluting the activated MAIT cell
supernatant reduced the suppression of HCV replication in a
dose-dependent manner (Fig. 7c). Addition of anti-IFN-g
reversed the HCV suppression by activated MAIT cell
supernatants (Fig. 7d). In an extension of the experimental set up
using virally-induced activation to trigger MAIT cells,
supernatants from MAIT cells incubated with HCV-treated
macrophages reduced HCV replication in the hepatocyte reporter
cell line compared to mock-treated macrophages (Supplementary
Fig. 10). These results indicate that activation of MAIT cells by
viral triggers induces responses that can impact on viral replica-
tion in vitro.
Discussion
MAIT cells are an abundant human T-cell population with a
semi-invariant TCR determining bacterial specificity. It has
previously been considered that MAIT cells were not responsive
to viral infection37. However, in this study we provide data to
show MAIT cells are also readily and specifically activated by
pathogenic viruses in vivo and in vitro. Furthermore, we define
mechanisms that allow this virally-driven activation, and show
they are distinct in the different viral settings.
The in vivo data shows that there is evidence of MAIT cell
activation in response to DENV, HCV and influenza virus.
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Figure 6 | MAIT cells respond to type I interferons in vitro and in vivo.
(a) PBMC’s from healthy individuals were directly stimulated for 24 h with
IFN-a, IFN-b, IL-12, IL-15, IL-18 or indicated combinations thereof. IFN-g
expression by MAIT cells (gated on live CD3þCD8þCD161þ þVa7.2þ
cells) was analysed by flow cytometry. (b–d) B18R (IFN-a/b neutralizing
protein) or PBS control were added to the co-culture (n¼6–11). IFN-g
(b), CD69 (c) and Granzyme B (d) expression is shown relative to the
control. Data are representative from at least two independent experiments.
(e) PBMC’s from healthy controls or HCV patients at baseline, during or
end of treatment with either SOFþRBV or SOFþRBV/PEG-IFN were
analysed by flow cytometry. CD69 expression on MAIT cells (gated on live
CD3þCD8þCD161þ þVa7.2þ cells) was measured. Bars represent
means±s.e.m. Statistical significance was determined with the
Kruskal–Wallis test followed by the Dunns’ test (a) or the Mann–Whitney
test (b–e). ns40.05, *P 0.05, ***Pr0.001, ****Pr0.0001. HC,
healthy controls.
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Of these the most striking is the data from acute DENV infection
as it is clear that such activation is profound and rapid in this
severe clinical setting. Of note, those patients who went on to
develop DHF exhibited significantly higher levels of activation as
judged by CD38 expression. This suggests the MAIT cell response
could contribute to the pathophysiology of this condition. The
correlation between levels of IL-18, levels of IL-18R and MAIT
cell activation suggests an important role for IL-18 in this
activation process, consistent with the in vitro mechanisms
demonstrated. In DENV, HCV and influenza virus infection we
found clear evidence of activation of the MAIT cells, as judged by
upregulation of Granzyme B (which is tightly regulated in
MAIT cells22). In addition, we noted a decrease in circulating
MAIT cell frequencies. The mechanism for this is not clear.
It may result from translocation of some cells from blood to
tissues, or it could result from activation-induced cell death as has
been suggested for HIV infection38.
The data presented are correlative—however probing a
non-redundant role in animal models is not straightforward.
In mice the MAIT cell population is a very small minority
compared to the frequencies of iNKT cells, which have
overlapping functions and innate cytokine responsiveness39. In
humans, the situation is reversed, with MAIT cell frequencies
exceeding those of iNKT cells by 1–2 logs13. Existing data indicate
a functional antiviral role for iNKT cells in control of virus
infections in tissues such as lung, in mouse models: given similar
molecular mechanisms of activation apply, and similar effector
functions are induced, it seems reasonable to extrapolate from
this that MAIT cell activity would have a parallel role in human
infection40. Emerging models with increased MAIT cell
frequencies in mice may help address this question using new
in vivo approaches41.
MR1 tetramers unequivocally identify MAIT cells, but these
reagents are not yet widely available. In this study we used
CD161þþVa7.2þ as a surrogate marker for MAIT cells, which
is a commonly used staining approach and includes the majority
of tetramer-positive MAIT cells6,42. We further defined MAIT
cells as CD8þCD4CD3þ T cells, and for in vitro experiments
PBMC’s from healthy individuals were used. CD8 is expressed by
the majority of MAIT cells, and CD4 only by a small proportion
of MAIT cells42. This approach has been used in recent
transcriptional studies and allows ready comparison with
related CD161-expressing subsets16. Future studies using MR1
tetramers are needed to further establish the distribution of MAIT
cell phenotype in virally infected humans in more detail. As we
did not have access to the tetramer, the observed loss of MAIT
cells in virally infected patients may be potentially explained by
down-regulation of CD161, as previously suggested12,43.
However, Fernandez et al.44 showed that in HIV-1 infected
patients, MR1 tetramers do not bind CD161Va7.2þ T cells,
and the loss of MAIT cells in the periphery may be due
to recruitment to the site of infection or activation-induced cell
death. Of note, our data are not restricted to CD161þþVa7.2þ
cells but also includes responses from the minority
CD161þþVa7.2 cells, which we have previously described as
sharing phenotypic and functional properties with MAIT cells
and which likely also include some recently described Va7.2
MR1-restricted T cell populations45,46.
The mechanisms we have explored reveal a central role for
IL-18 in virus-induced activation12,16. However, the critical
co-stimulation was not restricted to a single cytokine. In the
case of HCV we repeatedly observed an important role for IL-15.
IL-15 levels in these experimental conditions were very low,
but upregulation of IL-15R was seen and importantly antibody-
blockade of IL-15 revealed a clear role for this cytokine. In
addition, we observed a role for type I IFNs in the activation of
MAIT cells in response to HCV. This was clear in both addition
and blockade experiments and is consistent with data from
natural killer cells, where such cytokine-mediated activation is
described47.
The cytokine activation of MAIT cells was mediated by APCs
with a role for viral sensing and replication. In the case of DENV,
viral replication was required for MAIT cell activation and this
was positively correlated with the level of productive infection in
the APC. Although we observed a reduction of MAIT cell
activation in response to UV-irradiated HCV and IAV,
replication does not have a key role in this context, since
HCV and influenza poorly replicate in macrophages28,29. As APC
have continual and extensive endocytic activity, viral recognition
can occur through endocytosis of viral particles as well as through
direct infection26,48. Using TLR agonists, we found that both
surface and endocytic TLRs can trigger MAIT cells, in particular
viral pathogen-associated molecular patterns.
Using murine bone marrow-derived DCs, Le Bourhis et al.37
has previously shown that MAIT cells are not responsive to viral
infection. This discrepancy is likely due to the use of murine,
rather than human cells, which may reflect differential abilities in
secreting, as well as, responding to cytokines.
IFN-a-mediated activation of MAIT cells is clinically and
functionally relevant, as demonstrated in vivo in the well-
controlled BOSON clinical trial. In addition to directly acting
antiviral drugs (SOF in combination with RBV), IFN-a was
included in one arm only and associated with MAIT cell
activation and an enhanced therapy response36. It is possible
that MAIT cells act as local amplifiers of IFN-a-mediated
therapies, contributing to an antiviral effect through secretion of
further local antiviral cytokines or potentially via clearance of
infected cells. The specific activation by type I IFNs appears to be
important evidence in favour of an evolution of MAIT cells in
response to viral signals. Although type I IFN signalling is
not exclusive to virus infections, a wealth of data links IFN
pathways with antiviral defence, and we propose that MAIT cells
form an important part of this network in humans. Of note,
IFN-a signalling alone was insufficient to fully activate MAIT
cells, indicating a potentially fail-safe mechanism to prevent
harmful over-activation.
The secondary consequences of MAIT cell activation could be
of significance for both protection and immunopathology.
Activation of MAIT cells in tissues could provide both direct
and indirect antiviral effects. HCV, for example, is known to be
highly sensitive to T-cell-derived IFN-g49,50. Accordingly, we
found that activation of MAIT cells by HCV-induced responses
that limited HCV replication in vitro, in an IFN-g dependent
manner. Thus, the local activation of MAIT cells can be plausibly
correlated with a direct antiviral function in vivo.
Loss of MAIT cell frequencies (as we have observed in blood)
may contribute to impairment of both viral and bacterial control,
whereas excess cytokine secretion by MAIT cells may lead to
immunopathologic outcomes. For example, high levels of MAIT
cell activation could contribute to the cytokine ‘storm’ associated
with DHF and severe cases of influenza virus51,52. Activation-
induced loss of MAIT cells is potentially relevant in the context of
influenza virus infection, which is epidemiologically associated
with secondary bacterial pneumonia due to Staphylococcus aureus
or Streptococcus pneumonia53,54. Both of these organisms possess
the MAIT cell ligand7,37, and it is plausible that depletion of
MAIT cells in situ could lead to transient impairment of local
control of these pathogens. Interestingly, the transcription factor
PLZF, which likely drives the innate phenotype and functionality
of MAIT cells, may also contribute to the induction of activation-
induced cell death, through upregulation of specific intracellular
caspases55.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms11653
8 NATURE COMMUNICATIONS | 7:11653 | DOI: 10.1038/ncomms11653 | www.nature.com/naturecommunications
In conclusion, human MAIT cells are activated in response to
virus infections (as illustrated by a simplified model depicted
in Supplementary Fig. 11), through overlapping mechanisms
dependent on the virus and likely the environment and cell types
affected. These data extend the likely functions of these abundant
human lymphocytes well beyond their traditional confines.
Modulation of this cell subset (and related CD161þ T-cell
subsets16,56–58) could provide a novel opportunity to promote
antiviral defence or limit immunopathology.
Methods
Patient samples. All samples were collected with appropriate patient consent and
local research ethics committee approval. Samples were frozen and stored at
 80 C until examined. Healthy donors were supplied by the NHS blood service
without any further donor information. The study on DENV patient samples was
approved by the Scientific and Ethical Committee of the Khon Kaen Hospital in
Thailand and the Riverside Ethics Committee in the UK (06/Q0401/22).
Laboratory confirmation of DENV infection was determined by RT–PCR detection
of DENV nucleic acid (which also confirmed the infecting serotype) or
seroconversion in an ELISA of IgM. Secondary infection was defined based on the
ratio of DENV-specific IgM to IgG o1.2 on or after day 6 of illness. Disease
severity was classified according to 1997 World Health Organization criteria. Of
the patients enroled in the study, 10 patients were classified as mildly symptomatic
of dengue fever and 10 patients were classified as severely symptomatic of dengue
haemorrhagic fever with plasma leakage and bleeding (Supplementary Table 1).
The day of defervescence was defined as day 0, the day before defervescence as day
 1, the day after defervescence as day þ 1, and so forth. PBMCs were isolated
from whole blood by Ficoll-Hypaque density-gradient centrifugation at various
time points during hospitalization and cryopreserved until further use.
Patients with influenza virus infection requiring hospitalization were recruited
from two hospitals based in Oxford and Glasgow during the 2009 H1N1 pandemic
under ethical approval (09/H0606/92). Influenza virus infection was diagnosed
using an in-house generic influenza A real time PCR assay based on the Matrix
gene and confirmed with swine-origin H1N1/09 specific Matrix gene PCR59,60.
Patients had concomitant conditions as documented in Supplementary Table 2, but
were not on immunosuppressants or steroids at the point of sampling. Two
patients were pregnant, and one was 6 days post-partum. PBMC samples from
HCV patients (Supplementary Table 3) were collected from the Hepatitis Clinic at
the John Radcliffe Hospital, Oxford, UK and consented according to a locally
approved protocol (COREC 04.OXA.010). Liver biopsy specimens were obtained
from patients with HCV infection (n¼ 55) at S. Bortolo Hospital, Vicenza, Italy
and scored using the Ishak system. Control samples were normal adjacent tissue
from six uninfected volunteers undergoing liver resection for other reasons
(source Proteogenex, CA, USA). Trials were conducted in accordance with the
Declaration of Helsinki, ethical approval was obtained from local ethics
committees, and all patients provided written informed consent. Explanted
HCV-diseased liver tissues were obtained from QE transplant programme and
non-diseased normal liver tissue was obtained from donor liver tissue surplus to
clinical requirements. Normal liver was liver tissue from hepatic resection of
colorectal metastasis. For studying MAIT cell activation in the context of HCV
infection and type I IFNs in vivo, PBMC from the BOSON clinical trial were used,
as part of a collaboration between STOP-HCV and Gilead Sciences36,61. BOSON is
a randomized, open-label, phase 3 study testing SOF plus RBV with or without
pegylated IFN-a in patients with HCV genotype 3 and treatment-experienced
cirrhotic patients with HCV genotype 2 (Supplementary Table 4). This study was
registered with the European Clinical Trials Database, number 2013-002641-11.
Tissue staining. Paraffin-embedded human liver tissues sections were dewaxed
using Clearene and IMS. Endogenous peroxidase was blocked by using 5%
hydrogen peroxide followed by antigen retrieval using 10% EDTA buffer. Slides
were blocked using casein buffer. Primary Rabbit IL-18 antibody LS-B2809, 1:50
dilution was applied for an hour followed by Vector Impress anti-rabbit secondary
for 30min in a staining chamber with rocking. Slides were then washed with
PBSþTween and Impress DAB substrate was applied for 2½ mins. Slides were
then counterstained in Mayer’s haematoxylin and mounted in DPX.
Cell culture. Human PBMCs were isolated from leukocyte cones from healthy
donors supplied by the NHS blood service. CD8þ T-cells were isolated from
PBMCs using positive selection with MACS CD8þ microbeads (Miltenyi).
Monocytes were enriched from PBMCs using MACS CD14þ microbeads
(Miltenyi). Monocytes were differentiated into macrophages (macrophages or
GM-MF), by incubating the CD14þ cells for 7 days in X-VIVO15 (Lonza),
Pen/strep (Sigma-Aldrich), L-glutamine (Sigma-Aldrich) with 50 ngml 1 GM-CSF
(Miltenyi). Immature dendritic cells (imDC’s or DC’s) were obtained by culturing
CD14þ cells for 4–5 days in the presence of 20–100 ngml 1 GM-CSF
(Miltenyi/First Link) and 25 ngml 1 IL-4 (Miltenyi/eBioscience). Where stated,
MAIT cells were sorted using a Beckman Coulter MoFlo XDP.
Viruses. DENV serotype 2, strain 16681, was grown in C6/36 cells in Leibovitz’s
L-15 medium with L-glutamine and supplemented with 2% fetal calf serum.
Culture medium was centrifuged and stored at  80 C. The titres of virus were
determined by a focus-forming assay on Vero cells and expressed as focus-forming
units per ml. Briefly, virus was serially diluted and incubated with Vero cells for 2 h
at 37 C. The monolayers were then overlaid with 1.5% carboxymethylcellulose and
incubated at 37 C for 3 days. Virus foci were stained with anti-DENV E antibody
(4G2) followed by peroxidase-conjugated anti-mouse Ig and visualized by the
addition of DAB substrate. Infection rates of DENV infected DCs were assessed
using an antibody detecting the non-structural DENV protein, NS3, by flow
cytometry. The mouse monoclonal anti-DENV NS3 (E1D8) and anti-DENV E
(4G2) were gifts from E. Harris and AFRIMS.
A total of 10 ng RNA transcribed from genotype 2a HCV strain J6CF-JFH1
(obtained from Prof. Bartenschlager62) was electroporated into Huh-7.5 cells
(obtained from Apath) and were cultured for up to 3 weeks. Cell culture
supernatants were collected for up to 20 days post electroporation centrifuged and
concentrated using an Amicon Ultra-15 (Millipore). This inoculum was used to
infect huh-7.5 cells. The HCV titre was determined by immunofluorescence.
Huh-7.5 cells were fixed with methanolacetone, blocked with BSA/phosphate-
buffered saline (PBS) solution, washed with PBS, stained with anti-HCV core
primary antibody (Cambridge Biosciences), washed with PBS and Alexa Fluor 488
donkey polyclonal secondary antibody to Mouse IgG (ab150105, Abcam). To
measure HCV replication a HCV luciferase reporter Jc1FLAGp7-nsGluc2A29 virus
was used. Jc1FLAG(p7-nsGluc2A) was grown in naı¨ve Huh-7.5 cells63 and the
infectivity titre was determined by limiting dilution titration on naive Huh-7.5 cells
as median tissue culture infective dose (TCID50). To measure HCV replication,
Huh-7.5 cells were plated in a 96-well plate and infected at an MOI of 0.1 for 6 h.
After washing the Huh-7.5 cells, supernatants from (un)stimulated MAIT cells
were added in the presence or absence of a neutralizing IFN-g (clone MD-1,
14-7317-85 eBioscience). Supernatants were collected 4 days post infection and
luciferase expression determined using the Renilla Luciferase Assay System
(Promega) and a Berthold TriStar2 multimode reader LB 942.
Influenza A/WSN/33 (H1N1) virus (WSN) was grown in Madin Darby Bovine
Kidney (MDBK, obtained from the European Collection of Cell Cultures) cells in
Minimum Essential Medium Eagle (Sigma) with 2mM L-glutamine and 0.5% fetal
calf serum. To produce virus stocks, six 175 cm2 tissue culture flasks containing
sub-confluent MDBK cells were infected at low-multiplicity. After 48 h of culture in
a 37 C humidified incubator, supernatants were collected and clarified by
low-speed centrifugation (30min, 2,000 g and 30min, 18,000 g, 4 C). Next, WSN
was concentrated through a 30% sucrose cushion by ultracentrifugation (90min,
112,000 g, 4 C). Finally, WSN was purified on a 30–60% sucrose gradient by
ultracentrifugation (150min, 209,000 g, 4 C). The visible band of virus was drawn
off with a needle. (Hutchinson, E. and Fodor, E., Nature ProtocolExchange,
Purification of influenza virions by haemadsorption and ultracentrifugation,
‘http://www.nature.com/protocolexchange/protocols/3315’)64,65. Plaque assays
were performed on MDBK cells using standard techniques. Influenza A (H3N2)
virus A/England/691/2010 is a clinical strain isolated by Public Health England
(PHE), as part of the MOSAIC project. Influenza B virus, B/Florida/04/2006 was
derived from reverse genetics systems by de novo synthesis (GeneArt).
In vitro virus experiments. Unless specified differently, for co-culture experi-
ments using viruses, APCs were treated with virus at a MOI of 1, as determined
based on the viral titre and number of cells plated, for 90 to 120min at 37 C. Virus
was washed off and isolated CD8þ T-cells were added for an additional 10–24 h,
unless specified differently. In the case of the DENV experiments, PBMC’s were
added instead of isolated CD8þ T-cells. In the case of influenza virus, WSN virus
was used, unless specified differently.
In vitro cytokine stimulations. For cytokine stimulation experiments, isolated
CD8þ T-cells or PBMC’s were stimulated for 24 h with 50 ngml 1 IL-12
(Miltenyi Biotech), 50 ngml 1 IL-18 (R&D Systems Europe), 50 ngml 1 IL-15
(Miltenyi Biotech) or 2,000Uml 1 IFN-a (Sigma-Aldrich) or 50 ngml 1 IFN-b
(Miltenyi Biotech) or combinations thereof. For blocking experiments, neutralizing
agents were added into the culture together with the CD8þ T-cells or PBMC’s.
Blocking antibodies against IL-12p40/70 (508804, eBioscience), IL-12p70
(MAB219-100, R&D), IL-15 (MAB2471, R&D) or IL-18 (D044-3, MBL
International, USA), IFN-g (14-7317-85, eBioscience) or MR1 (361102, Biolegend)
were used at 5–10 mgml 1. Type I IFN was blocked using 1 mgml 1 B18R
(34-8185-81, eBioscience).
Flow cytometry. Antibodies/dyes and dilutions used were: viability dye live/dead
fixable-violet (L34955, Invitrogen, 1:1250), CD3-eFluor450 (48-0038, eBioscience,
1:100), CD3-PECy7 (25-0038, eBioscience, 1:100), CD4-VioGreen (130-096-900,
Miltenyi Biotech, 1:50), CD8-VioGreen (130-098-062, Miltenyi Biotech, 1:50),
CD8-V450 (560347, BD, 1:50), CD8-PerCP.Cy5.5/PerCP (301032, Biolegend,
1:100), CD38-APC (555462, BD, 1:50), CD69-FITC (11-0699, eBioscience, 1:40),
CD161-APC (130-098-908, Miltenyi Biotech, 1:100), CD161-PE (130-099-193,
Miltenyi Biotech, 1:100), IFN-g-FITC (130-091-641, Miltenyi Biotech, 1:50),
IFN-g-APCCy7 (502529 Biolegend, 1:50), Va7.2-PE/PeCy7/APC/FITC
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(351705/351711/351707/351703, Biolegend, 1:50). Granzyme B-APC (MHGB05,
Invitrogen), IL-18Ra-APC (17-7183-41, eBioscience, 1:50), TNF-a-PeCy7
(502929, Biolegend, 1:100). All data was acquired on a MACSQuant (Miltenyi
Biotech) or a BD FACSVerse (BD) and analyzed on FlowJo (Tree Star Inc.).
Gating strategy is shown in Supplementary Fig. 12.
Cytokine measurements. Cytokines levels in this study were measured from cell
culture supernatants or heparin plasma samples. Cell culture supernatants from
macrophages treated with mock, HCV or influenza A were collected at 48 h. Cell
culture supernatants from DCs treated with mock or DENV were collected at 42 h.
Heparin plasma samples were collected from DENV infected patients at different
phases of illness or from healthy controls. Cell culture supernatants and heparin
plasma samples were frozen at  80˚C until further use. Cytokine levels were
analysed using Bio-Plex human cytokine kits (BioRad) and acquired on a Luminex
100 (Luminex) or a Bio-Plex 200 reader (BioRad) according to the manufacturer’s
instructions.
Statistical analysis. Statistical analysis was carried out with GraphPad Prism
software. Statistical significance was reported as ns P40.05; *Pr0.05; **Pr0.01;
***Pr0.001; ****Pr0.0001. Error bars on graphs represent s.e.m. Mann–Whitney
test was used to calculate significance levels between two groups. Wilcoxon mat-
ched-paired test was used to calculate significance levels between two paired
groups. For comparisons of means from multiple groups against one control group
the Kruskal–Wallis with Dunn’s multiple comparison post-test analysis was per-
formed. Spearman-rank correlation analysis was used to calculate correlations.
Sample sizes were adequate to detect large effects between groups, as determined by
the reproducibility and variability of each particular experiment and limited by the
availability of patient samples. No randomization or blinding was used.
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